Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists

Por um escritor misterioso
Last updated 12 abril 2025
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors - ScienceDirect
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
WO2014033122A1 - Inhibitors of cd40-traf6 interaction - Google Patents
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
Sophie GONG, Sr. scientist, GlaxoSmithKline, London, GSK, R&D China
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
1-(3-tert-butylsulfonyl-4-cyano-2-hydroxyphenyl)-3 -[(1R)-2-methylcyclopent-2-en-1-yl]urea, C18H23N3O4S
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
Development of fluorescent peptide G protein‐coupled receptor activation biosensors for NanoBRET characterization of intracellular allosteric modulators - Farmer - 2022 - The FASEB Journal - Wiley Online Library
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis - ScienceDirect
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
WO2014033122A1 - Inhibitors of cd40-traf6 interaction - Google Patents
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
CXCR2-IN-2, CXCR2 Antagonist
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors - ScienceDirect
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain  Penetrant, and Orally Bioavailable CXCR2 Antagonists
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists

© 2014-2025 trend-media.tv. All rights reserved.